OTC · Biotechnology

IMV Inc. (IMVIF) Stock

$0.00 OTC: IMVIF Healthcare

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage.

Valuation

MetricValue
Price$0.00
Market Cap$23423
P/E Ratio-0.18
P/B Ratio-1.01
P/S Ratio0.00
EPS (TTM)$-4.37
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE514.29%
ROA-116.13%
ROCE-180.11%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-4.14
Current Ratio3.11

Annual Financials (USD)

Metric20182019202020212022
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-22.0M$-35.0M$-40.0M$-39.0M
Net Profit$-22.0M$-21.0M$-27.0M$-36.0M$-36.0M
EPS$-5.00$-4.25$-4.55$-4.89$-4.37
Op Margin-18818.4%-49124.1%-1117136.4%——

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$23.0M$17.0M$46.0M$50.0M$31.0M
Total Liabilities$19.0M$12.0M$15.0M$29.0M$38.0M
Cash$15.0M$11.0M$36.0M$39.0M$21.0M
Borrowings$10.0M$8.0M$8.0M$20.0M$29.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-17.0M$-21.0M$-25.0M$-32.0M$-32.0M
Investing Cash Flow$-4.0M$-1.0M$-1.0M$-3.0M$-2.0M
Financing Cash Flow$1.0M$5.0M$0$-3.0M$-2.0M
Net Cash Flow$-1.0M$0$25.0M$2.0M$-17.0M
Free Cash Flow$-19.0M$-21.0M$-25.0M$-33.0M$-33.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-0.47
FCF Yield-369.80%
Quick Ratio2.93
Interest Coverage-78.83
Return 1Y1900.00%
Return 3Y-95.00%
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Kohmann Bosshard Financial Services, LLC302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADYXAdynxx, Inc. $0.00 — 0.00 $581 0.00%
ATRXAdhera Therapeutics Inc $0.00 — 0.00 $722 0.00%
BIMIBIMI International Medical Inc. $0.00 — 0.00 $1156 0.00%
CFRXQContraFect Corp. $0.00 — 0.00 $107 0.00%
DMKPQDMK Pharmaceuticals Corporation $0.00 — 0.00 $1010 0.00%

About IMV Inc.

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers. The flagship therapeutic, maveropepimut-S, is an immunotherapy derived from the DPX platform, specifically engineered to attack cells expressing survivin. This compound is currently advancing through Phase II clinical studies for diffuse large B-cell lymphoma, ovarian cancer, and a variety of solid tumors including those affecting the bladder, liver, and MSI-H positive types. It is also in Phase I investigation for breast cancer. Additionally, the company's pipeline includes DPX-SurMAGE, undergoing Phase I clinical evaluation for bladder cancer, alongside the development of DPX-COVID-19 and DPX-RSV for addressing infectious diseases. The entity, previously known as Immunovaccine Inc., formally adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its corporate headquarters in Dartmouth, Canada.

IMV Inc. (IMVIF) stock trades at $0.00 with a market capitalization of $23423. The stock is valued at a price-to-earnings (P/E) ratio of -0.18, price-to-book of -1.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, IMV Inc. generates a return on equity (ROE) of 514.29% — well above the market average, a sign of a high-quality business, return on capital employed of -180.11%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: imvaccine.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides